Merck’s high-profile suit Tuesday alleging HHS’ Medicare drug price negotiation policies are coercive and violate drug makers’ First and Fifth Amendment rights says Congress should have instead empowered HHS to either set a maximum amount the government would pay for covered drugs or to use its natural leverage to obtain more favorable drug prices.